APO-DAPAGLIFLOZIN-METFORMIN TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Prieinama:

APOTEX INC

ATC kodas:

A10BD15

INN (Tarptautinis Pavadinimas):

METFORMIN AND DAPAGLIFLOZIN

Dozė:

5MG; 1000MG

Vaisto forma:

TABLET

Sudėtis:

DAPAGLIFLOZIN 5MG; METFORMIN HYDROCHLORIDE 1000MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

15G/50G

Recepto tipas:

Prescription

Produkto santrauka:

Active ingredient group (AIG) number: 0257650002; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2023-05-16

Prekės savybės

_APO-DAPAGLIFLOZIN-METFORMIN (dapagliflozin and metformin
hydrochloride tablets) _
_Page 1 of 85 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
APO-DAPAGLIFLOZIN-METFORMIN
Dapagliflozin and Metformin Hydrochloride tablets
Tablets, 5 mg dapagliflozin / 850 mg metformin hydrochloride,
5 mg dapagliflozin / 1000 mg metformin hydrochloride,
for oral use
Combination of oral blood glucose lowering drugs
Apotex Inc.
150 Signet Drive
Toronto, Ontario
M9L 1T9
Date of Initial Authorization:
MAY 16, 2023
Date of Revision:
SEP 19, 2023
Submission Control Number: 275438
_APO-DAPAGLIFLOZIN-METFORMIN (dapagliflozin and metformin
hydrochloride tablets) _
_Page 2 of 85 _
RECENT MAJOR LABEL CHANGES
1. INDICATIONS. 1.2 Geriatrics
09/2023
2 CONTRAINDICATIONS
09/2023
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
09/2023
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and
Dosage Adjustment
09/2023
4 DOSAGE AND ADMINISTRATION, 4.4 Administration
09/2023
7 WARNINGS AND PRECAUTIONS, Driving and Operating Machinery
09/2023
7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism
09/2023
7 WARNINGS AND PRECAUTIONS, Hematologic
09/2023
7 WARNINGS AND PRECAUTIONS,
Hepatic/Biliary/Pancreatic
09/2023
7 WARNINGS AND PRECAUTIONS,
Monitoring and Laboratory Tests
09/2023
7 WARNINGS AND PRECAUTIONS,
Neurologic
09/2023
7 WARNINGS AND PRECAUTIONS,
Renal
09/2023
7.1.4 Geriatrics
09/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
5
1
INDICATIONS
................................................................................................................
5
1.1
Pediatrics
....................................